Literature DB >> 33064898

Yield of colorectal cancer at colonoscopy according to faecal haemoglobin concentration in symptomatic patients referred from primary care.

Stephen T McSorley1, Jayne Digby2, Danielle Clyde3, Neil Cruickshank3, Paul Burton4, Louise Barker3, Judith A Strachan5, Callum G Fraser2, Karen Smith6, Craig Mowat7, Jack Winter8, Robert J C Steele2.   

Abstract

AIM: Lower gastrointestinal (GI) symptoms are poor predictors of colorectal cancer (CRC). The aim of this study was to examine the diagnostic yield of colonoscopy by faecal haemoglobin (f-Hb) concentration in symptomatic patients assessed in primary care by faecal immunochemical testing (FIT).
METHOD: In three Scottish NHS Boards, FIT kits (HM-JACKarc, Hitachi Chemical Diagnostics Systems Co., Ltd, Tokyo, Japan) were used by general practitioners to guide referrals for patients with lower GI symptoms (laboratory data studied for 12 months from December 2015 onwards in Tayside, 18 months from June 2018 onwards in Fife and 5 months from September 2018 onwards in Greater Glasgow and Clyde). Cases of CRC diagnosed at colonoscopy were ascertained from colonoscopy and pathology records.
RESULTS: Four thousand eight hundred and forty one symptomatic patients who underwent colonoscopy after FIT submission were included. Of the 2166 patients (44.7%) with f-Hb <10 µg Hb/g faeces (µg/g), 14 (0.6%) were diagnosed with CRC, with a number needed to scope (NNS) of 155. Of the 2675 patients (55.3%) with f-Hb ≥10 µg/g, 252 were diagnosed with CRC (9.4%) with a NNS of 11. Of the 705 patients with f-Hb ≥400 µg/g, 158 (22.4%) were diagnosed with CRC with a NNS of 5. Over half of those diagnosed with CRC with f-Hb <10 µg/g had coexisting anaemia.
CONCLUSION: Symptomatic patients with f-Hb ≥10 µg/g should undergo further investigation for CRC, while higher f-Hb concentrations could be used to triage for urgency during the COVID-19 recovery phase. Patients with f-Hb <10 µg/g and without anaemia are very unlikely to be diagnosed with CRC and the majority need no further investigation.
© 2020 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Keywords:  colonoscopy; colorectal cancer; faecal haemoglobin; faecal immunochemical test; gastrointestinal symptoms

Year:  2020        PMID: 33064898     DOI: 10.1111/codi.15405

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  7 in total

1.  Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC): a joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the British Society of Gastroenterology (BSG).

Authors:  Kevin J Monahan; Michael M Davies; Muti Abulafi; Ayan Banerjea; Brian D Nicholson; Ramesh Arasaradnam; Neil Barker; Sally Benton; Richard Booth; David Burling; Rachel Victoria Carten; Nigel D'Souza; James Edward East; Jos Kleijnen; Michael Machesney; Maria Pettman; Jenny Pipe; Lance Saker; Linda Sharp; James Stephenson; Robert Jc Steele
Journal:  Gut       Date:  2022-07-12       Impact factor: 31.793

2.  Faecal haemoglobin concentration thresholds for reassurance and urgent investigation for colorectal cancer based on a faecal immunochemical test in symptomatic patients in primary care.

Authors:  Craig Mowat; Jayne Digby; Judith A Strachan; Rebecca K McCann; Francis A Carey; Callum G Fraser; Robert Jc Steele
Journal:  Ann Clin Biochem       Date:  2021-01-21       Impact factor: 2.057

3.  The use of faecal haemoglobin in deciding which patients presenting to primary care require further investigation (and how quickly) - the FIT approach.

Authors:  Judith A Strachan; Craig Mowat
Journal:  EJIFCC       Date:  2021-02-28

4.  Combining the quantitative faecal immunochemical test and full blood count reliably rules out colorectal cancer in a symptomatic patient referral pathway.

Authors:  Mark S Johnstone; Paul Burton; Georgios Kourounis; Jack Winter; Emilia Crighton; David Mansouri; Paul Witherspoon; Karen Smith; Stephen T McSorley
Journal:  Int J Colorectal Dis       Date:  2021-12-21       Impact factor: 2.571

5.  Combining faecal immunochemical testing with blood test results for colorectal cancer risk stratification: a consecutive cohort of 16,604 patients presenting to primary care.

Authors:  Diana R Withrow; Brian Shine; Jason Oke; Andres Tamm; Tim James; Eva Morris; Jim Davies; Steve Harris; James E East; Brian D Nicholson
Journal:  BMC Med       Date:  2022-03-15       Impact factor: 8.775

6.  Role of the faecal immunochemical test in patients with risk-stratified suspected colorectal cancer symptoms: A systematic review and meta-analysis to inform the ACPGBI/BSG guidelines.

Authors:  Richard Booth; Rachel Carten; Nigel D'Souza; Marie Westwood; Jos Kleijnen; Muti Abulafi
Journal:  Lancet Reg Health Eur       Date:  2022-10-03

7.  Alternative diagnoses and demographics associated with a raised quantitative faecal immunochemical test in symptomatic patients.

Authors:  Mark S Johnstone; Gillian Miller; Grace Pang; Paul Burton; Georgios Kourounis; Jack Winter; Emilia Crighton; David Mansouri; Paul Witherspoon; Karen Smith; Stephen T McSorley
Journal:  Ann Clin Biochem       Date:  2022-03-03       Impact factor: 2.587

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.